10 results on '"Ngolle M"'
Search Results
2. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients : ANRS 12115 DAYANA substudy
- Author
-
Le, M. P., Landman, R., Koulla-Shiro, S., Charpentier, C., Sow, P. S., Diallo, M. B., Gueye, N. F. N., Ngolle, M., Le Moing, V., Eymard-Duvernay, Sabrina, Benalycherif, A., Delaporte, Eric, Girard, P. M., and Peytavin, G.
- Subjects
drug monitoring ,immune system diseases ,antiretroviral therapy ,virus diseases ,urologic and male genital diseases ,ART - Abstract
Objectives: An open-label randomized trial (DAYANA) was conducted in sub-Saharan settings to evaluate four different regimens containing tenofovir disoproxil fumarate as first-line treatment for HIV infection. The objectives of the present substudy were to assess the relationship between trough concentrations of tenofovir in plasma collected after 24 h (C-24) and estimated glomerular filtration rates (eGFR) calculated by the different formulae that are available. Methods: The criteria for eligibility were those of the DAYANA trial, recruiting naive patients. The four tenofovir regimens were: Group 1, tenofovir/emtricitabine/nevirapine; Group 2, tenofovir/lopinavir/ritonavir; Group 3, tenofovir/emtricitabine/zidovudine; and Group 4, tenofovir/emtricitabine/efavirenz. The C-24 of tenofovir was determined using LC-MS/MS. The eGFR was calculated using the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae. Results: The median C-24 of tenofovir was 42 ng/mL. The C-24 of tenofovir was higher with lopinavir/ritonavir than with the other three regimens: at Week 4, 84 ng/mL versus 25 ng/mL; and at Week 48, 81 ng/mL versus 52 ng/mL. The baseline merged eGFR was 98.2 mL/min/1.73 m(2) with the CKD-EPI equation. Only the mean changes in eGFR in Group 2 differed from the absolute value of zero (-.2 mL/min/1.73 m(2)) with the CKD-EPI equation between baseline and Week 48. The Cockcroft-Gault formula is inappropriate for these African patients because it underestimated the baseline eGFR and overestimated the changes in eGFR between baseline and Week 48. Conclusions: In this population of mostly female HIV-1-infected African patients, tenofovir plasma overexposure was associated with PI/ritonavir and a time-dependent decrease in eGFR, probably via an inhibition of MRP2/MRP4 efflux transporters. The close monitoring over time of the eGFR using MDRD or CKD-EPI calculations and by using other biomarkers of renal disorder should be proposed as an alternative to therapeutic drug monitoring in resource-limited countries.
- Published
- 2015
3. Genotypic subtypes of HIV-1 in Cameroon
- Author
-
Nkengasong, J.N., Janssens, W., Heyndrickx, L., Fransen, K., Ndumbe, P.M., Motte, J., Leonaers, A., Ngolle, M., Ayuk, J., Piot, P., and Vandergroen, G.
- Subjects
HIV (Viruses) -- Genetic aspects - Abstract
Nkengasong, J.N.; Janssens, W.; Heyndrickx, L.; Fransen, K.; Ndumbe, P.M.; Motte, J.; Leonaers, A.; Ngolle, M.; Ayuk, J.; Piot, P.; Vandergroen, G. "Genotypic Subtypes of HIV-1 in Cameroon." AIDS, October [...]
- Published
- 1994
4. HIV-1 subtypes in Cameroon
- Author
-
Nkengasong, J.N., Janssens, W., Heyndrickx, L., Ndumbe, P., Fransen, K., Leonaers, A., Motte, J., Ngolle, M., Ayuk, J., Piot, P., and Groen, G. van der
- Subjects
HIV (Viruses) -- Genetic aspects ,Cameroon -- Health aspects - Abstract
AUTHORS: J.N. Nkengasong( 1), W. Janssens( 1), L. Heyndrickx( 1), P. Ndumbe( 2), K. Fransen( 1), A. Leonaers( 1), J. Motte( 1), M. Ngolle( 3), J. Ayuk( 3), P. Piot( [...]
- Published
- 1994
5. Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).
- Author
-
Delaugerre C, Nere ML, Eymard-Duvernay S, Armero A, Ciaffi L, Koulla-Shiro S, Sawadogo A, Ngom Gueye NF, Ndour CT, Mpoudi Ngolle M, Amara A, Chaix ML, and Reynes J
- Subjects
- Drug Resistance, Viral, High-Throughput Nucleotide Sequencing, Humans, Lamivudine therapeutic use, Mutation, Protease Inhibitors therapeutic use, Viral Load, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV-1 genetics
- Abstract
Background: The ANRS12286/MOBIDIP trial showed that boosted protease inhibitor (bPI) plus lamivudine dual therapy was superior to bPI monotherapy as maintenance treatment in subjects with a history of M184V mutation., Objectives: We aimed to deep analyse the detection of M184V/I variants at time of switch and at the time of virological failure (VF)., Methods: Ultra-deep sequencing (UDS) was performed on proviral HIV-DNA at inclusion among 265 patients enrolled in the ANRS 12026/MOBIDIP trial, and on plasma from 31 patients experiencing VF. The proportion of M184V/I variants was described and the association between the M184V/I mutation at 1% of threshold and VF was explored with logistic regression models., Results: M184V and I mutations were detected in HIV-DNA for 173/252 (69%) and 31/252 (12%) of participants, respectively. Longer duration of first-line treatment, higher plasma viral load at first-line treatment failure and higher baseline HIV-DNA load were associated with the archived M184V. M184I mutation was always associated with a STOP codon, suggesting defective virus. The 48 week estimated probability of remaining free from VF was comparable with or without the M184V/I mutation for dual therapy. At failure, M184V and major PI mutations were detected in 1/17 and 5/15 patients in the bPI arm and in 2/2 and 0/3 in the bPI+lamivudine arm, respectively., Conclusions: Using UDS evidenced that archiving of M184V in HIV-DNA is heterogeneous despite past historical M184V in 96% of cases. The antiviral efficacy of lamivudine-based dual therapy regimens is mainly due to the residual lamivudine activity., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
6. Getting pregnant in HIV clinical trials: women's choice and safety needs. The experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials.
- Author
-
Serris A, Zoungrana J, Diallo M, Toby R, Mpoudi Ngolle M, Le Gac S, Coutherut J, Cournil A, De Beaudrap P, Koulla-Shiro S, Delaporte E, and Ciaffi L
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Clinical Trials as Topic, Female, Follow-Up Studies, HIV Infections diagnosis, HIV Infections drug therapy, Humans, Multicenter Studies as Topic, Pregnancy, Pregnancy Outcome, Pregnancy Rate, Proportional Hazards Models, Randomized Controlled Trials as Topic, Reproduction, Reproductive Behavior psychology, Reproductive Behavior statistics & numerical data, Time Factors, Viral Load, Young Adult, HIV Infections epidemiology, Pregnancy Complications, Infectious epidemiology
- Abstract
Introduction: Pregnancy is an exclusion criteria in most clinical trials involving antiretroviral therapy (ART) and modern contraception methods are systematically proposed to women of childbearing age. Nevertheless pregnancies are often observed. Reproductive choices during clinical trials should be understood to adapt interventions to the level of risk for mother and baby safety. Our goal was to describe the reproductive behavior and pregnancy outcomes among HIV-infected women on second-line antiretroviral treatment enrolled in two clinical trials and to compare them with those of HIV-positive women in non-research settings., Methods: The number and outcomes of pregnancies were recorded among 281 non menopausal women enrolled in the ANRS 12169-2LADY and ANRS 12286-MOBIDIP clinical trials in Cameroon, Senegal and Burkina Faso. All participants had agreed to use a least one contraceptive method (barrier or non-barrier) which was provided for free during the study. Data were collected through revision of pregnancy notification forms and by data extraction from the study database, regularly updated and checked during the study., Results: Sixty-six women had 84 pregnancies between January 2010 and July 2015 resulting in a pregnancy rate of 8.0 per 100 women-years (WY) (95% CI 6.5-9.9) which is similar to the ones observed in cohort studies in Sub-Saharan Africa (varying from 2.5 to 9.4 pregnancies per 100 WY). Among 60 live births, 10 (16.6%) were born prematurely and 9 (15%) had a low birth weight. Sixteen miscarriages/stillbirths occurred (19.5%). This percentage is comparable to the one expected in the seronegative population which is reassuring for HIV-positive women considering pregnancy on ART. Only one minor birth defect was diagnosed. In univariate and multivariate analysis, miscarriages/stillbirths were not associated either with age, nadir of CD4 count, duration of ART, CD4 count, or viral load at the beginning of pregnancy., Conclusion: HIV-positive women participating in clinical trials conducted in Sub-Saharan Africa tend to get pregnant as often as seropositive women who received medical care in non-research settings. It is therefore essential to adopt a pragmatic approach by re-evaluating the relevance of the criteria for exclusion of pregnant women according to the risk associated with exposure and to seek more effective and innovating contraceptive strategies when using potentially teratogenic molecules.
- Published
- 2016
- Full Text
- View/download PDF
7. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
- Author
-
Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, and Girard PM
- Subjects
- Adenine administration & dosage, Adenine adverse effects, Adenine therapeutic use, Adult, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cameroon, Drug Therapy, Combination, Female, Follow-Up Studies, Genotype, HIV Infections immunology, HIV Infections virology, Humans, Male, Medication Adherence, Middle Aged, Organophosphonates administration & dosage, Organophosphonates adverse effects, Senegal, Tenofovir, Treatment Outcome, Viral Load, Young Adult, Adenine analogs & derivatives, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV-1 genetics, Organophosphonates therapeutic use
- Abstract
Background: The aim of the present study was to determine appropriate tenofovir-based regimens meriting evaluation in large-scale randomized trials among sub-Saharan African patients., Methods: This was a randomized open-label 96-week prospective pilot study evaluating four first-line regimens: tenofovir/emtricitabine/nevirapine (group 1), tenofovir/lopinavir/ritonavir (group 2), tenofovir/emtricitabine/zidovudine (group 3) and tenofovir/emtricitabine/efavirenz (group 4) in antiretroviral-naive, HIV-1-infected patients in Senegal and Cameroon. The primary end point was defined as an HIV-1 RNA viral load <50 copies/ml (study detection limit) at week 16 in ≥50% of patients using intention-to-treat analysis., Results: At baseline, 119 patients included were 34% male, had a median plasma viral load of 5.4 log10 copies/ml and median CD4(+) T-cell count of 200 cells/mm(3) (range 53-358). The primary end point was achieved for groups 1, 3 and 4 (58% [n=31], 62% [n=29] and 53% [n=30], respectively), but not for group 2 (38% [n=29]). At week 96, undetectable HIV-1 RNA had been achieved in 74% of patients in group 1, 38% in group 2, 72% in group 3 and 73% in group 4. Patients with detectable HIV-1 RNA at week 16 were more likely to have baseline HIV-1 RNA≥100,000 copies/ml (adjusted OR 5.56, 95% CI 1.72, 16.67). HIV mutations associated with protease inhibitor resistance emerged in three patients, all of whom were in group 2. Anaemia occurred in two group 3 patients and was the only serious treatment-related adverse event., Conclusions: Three efficient and safe tenofovir-based triple regimens were identified; the two-drug regimen (tenofovir/lopinavir/ritonavir) did not achieve the protocol-defined virological threshold of efficacy.
- Published
- 2014
- Full Text
- View/download PDF
8. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
- Author
-
Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene YM, Essomba C, Calmy A, Mpoudi-Ngolé E, Delaporte E, and Koulla-Shiro S
- Subjects
- Adult, Drug Therapy, Combination, Female, HIV Infections blood, HIV Infections virology, Humans, Male, Viral Load, Anti-HIV Agents therapeutic use, Drug Monitoring, HIV Infections drug therapy, Nevirapine blood, Patient Compliance
- Abstract
Objectives: To compare adherence to antiretroviral therapy using drug level monitoring and self-report and to explore the relation between these 2 methods and viral load measurements., Methods: Sixty patients received a fixed-dose combination of nevirapine, stavudine, and lamivudine in a clinical study in Cameroon. Adherence was assessed every 6 months until month 36 by nevirapine minimal plasma concentration and self-report. Plasma HIV-1 viral load was determined at the same time. Analyses included 159 complete observations., Results: The proportion of patients labeled as "adherent" was significantly lower using nevirapine monitoring (88.7%, 95% confidence interval [CI]: 82.7 to 93.2) than self-report (97.5%, CI: 93.7 to 99.3; P = 0.002). Virologic failure was associated with the nevirapine concentration (adjusted odds ratio [aOR] = 4.43; P = 0.018) but not with the self-reported adherence (aOR = 0.84; P = 0.9). As compared with the virologic outcome, the sensitivity of nevirapine level monitoring for predicting inadequate adherence was 20.5%, the specificity was 91.7%, the positive predictive value was 44.4%, and the negative predictive value was 78.0%. For self-report, the respective values were 2.6%, 97.5%, 25.0%, and 75.5%., Conclusions: Drug level monitoring provided a more reliable estimate of adherence than self-report. This method could be used in research settings. Operational research is required to define how to improve the accuracy of the self-report method because it is the most feasible method in clinical practice.
- Published
- 2008
- Full Text
- View/download PDF
9. Genotypic subtypes of HIV-1 in Cameroon.
- Author
-
Nkengasong JN, Janssens W, Heyndrickx L, Fransen K, Ndumbe PM, Motte J, Leonaers A, Ngolle M, Ayuk J, and Piot P
- Subjects
- Amino Acid Sequence, Base Sequence, Cameroon, Cloning, Molecular, DNA Primers, Genes, env, Geography, Glycosylation, HIV Envelope Protein gp41 biosynthesis, HIV-1 isolation & purification, Humans, Lymphocytes virology, Molecular Sequence Data, Polymerase Chain Reaction methods, Sequence Homology, Amino Acid, HIV Seropositivity virology, HIV-1 classification, HIV-1 genetics, Phylogeny
- Abstract
Objective: The only two HIV-1 strains (ANT70 and MVP5180) reported to date from Cameroon are members of the outlier clade (group O). In this study, we assessed the prevalence of group O viruses and other HIV-1 subtypes in Cameroon., Design: A phylogenetic analysis of 18 HIV-1 strains isolated from seropositive individuals from Yaoundé and Douala, Cameroon., Methods: A 900 base-pair fragment of the env gene coding for V3, V4, V5, and the beginning of gp41 of 17 out of 18 HIV-1 isolates from Cameroon was amplified, cloned and sequenced using polymerase chain reaction. A phylogenetic tree was constructed., Results: The overall env nucleotide sequence divergence among the Cameroon isolates ranged from 6.1 to 27.5%. In a phylogenetic tree, six subtypes were identified when compared with 23 reference strains of different geographic origin. Of these 17 Cameroonian strains, 11 (61%) were of subtype A of which the interpatient distances at the sequence level varied from 6.1% to 18.3% (average, 11.9%). Three (17%) strains were of subtype F, and the other three strains (6% each) belonged to subtypes B, E and H, respectively. The remaining isolate was classified as belonging to group O, on the basis of the sequence of part of the pol gene. A very broad spectrum of different tetrameric amino-acid sequences was observed at the apex of the V3 loop. Eleven strains contained the tetrameric globally predominant GPGQ sequence at the tip of the V3 motif. Two strains had the GPGR sequence typical of the American and European HIV-1 strains. The remaining tetrameric sequences included GPGS, GSGQ, GRGQ, and GLGR., Conclusion: These findings on a limited number of viruses suggest extensive env gene diversity of HIV-1 strains from Cameroon, and could have implications for vaccine development in Africa.
- Published
- 1994
- Full Text
- View/download PDF
10. Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
- Author
-
Nkengasong JN, Peeters M, Ndumbe P, Janssens W, Willems B, Fransen K, Ngolle M, Piot P, and van der Groen G
- Subjects
- Acquired Immunodeficiency Syndrome blood, Africa, Amino Acid Sequence, Belgium, Enzyme-Linked Immunosorbent Assay, Genotype, HIV Antibodies immunology, HIV-1 genetics, HIV-1 isolation & purification, Humans, Molecular Sequence Data, Neutralization Tests, Peptides chemical synthesis, Peptides immunology, Acquired Immunodeficiency Syndrome immunology, HIV Antibodies blood, HIV-1 immunology
- Abstract
Objectives: To determine the neutralizing antibody patterns to HIV-1ANT70 (ANT70) and HIV-1IIIB (IIIB) in human sera obtained from HIV-1-infected individuals from different African countries and Belgium. Second, to correlate the presence of neutralizing antibodies in sera and their ability to bind to synthetic peptides derived from eight different HIV-1 V3 loop sequences., Design and Methods: Forty sera from Belgium and 88 obtained from seven countries in Africa were tested for their ability to neutralize ANT70 (one of the most genetically divergent HIV-1 isolates documented), and IIIB. Sera found to cross-neutralize both viruses were further challenged with four HIV-1 field isolates. All sera were tested on a panel of V3 loop peptides obtained from different HIV-1 genotypes., Results: Four patterns of sera were identified, including 33 (26%) sera not neutralizing any of the isolates, seven (5%) sera neutralizing only ANT70, 45 (35%) sera neutralizing only IIIB, and 43 (34%) sera cross-neutralizing both isolates. Sera capable of cross-neutralizing both ANT70 and IIIB consistently neutralized other field isolates tested, with a remarkable similarity in neutralizing antibody titre. A significantly higher number of sera cross-neutralizing both ANT70 and IIIB compared with sera lacking neutralizing antibodies, reacted simultaneously in enzyme-linked immunosorbent assays (ELISA) with three or more V3 loop peptides belonging to HIV-1 strains of different genotypes. However, none of the sera cross-neutralizing ANT70 and IIIB were reactive in ELISA with the ANT70 V3 loop peptide., Conclusion: These results suggest that despite pronounced genomic variation of the HIV-1ANT70 isolate, there are strongly conserved neutralizing epitopes situated outside the V3 loop that are shared by other HIV-1 isolates. These findings suggest that genetic variation might be surmountable in the design of a polyvalent HIV vaccine, if neutralizing antibodies are found to be correlates of protection in HIV infection.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.